Literature DB >> 21326591

Palliative nonvascular interventions.

Kent T Sato1, Christopher Takehana.   

Abstract

Interventional radiologists are often called on to help with quality of life issues in end-stage cancer patients. Many times, the discomfort can be directly associated to the tumor mass itself, but in other instances, tumors can cause secondary obstruction of normal structures that can lead to patient distress. As with most palliative care patients, their medical conditions are not conducive to major surgery; therefore minimally invasive techniques are ideal for the treatment of these conditions. The following discussion addresses the various nonvascular interventions available to these patients, including the indications and limitations of these procedures.

Entities:  

Keywords:  Biliary obstruction; gastric outlet obstruction; hydronephrosis/hydroureter

Year:  2007        PMID: 21326591      PMCID: PMC3037253          DOI: 10.1055/s-2007-992327

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  48 in total

Review 1.  Surgical treatment of gastric cancer. Proximal, mid, and distal stomach.

Authors:  J W Smith; M F Brennan
Journal:  Surg Clin North Am       Date:  1992-04       Impact factor: 2.741

2.  Malignant gastroduodenal obstruction: palliation with self-expanding metallic stents.

Authors:  Bertrand Bessoud; Thierry de Baere; Alban Denys; Viseth Kuoch; Michel Ducreux; Sophie Precetti; Alain Roche; Yves Menu
Journal:  J Vasc Interv Radiol       Date:  2005-02       Impact factor: 3.464

3.  Symptom relief and quality of life after stenting for malignant bile duct obstruction.

Authors:  A B Ballinger; M McHugh; S M Catnach; E M Alstead; M L Clark
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

4.  Long-term results of percutaneous transhepatic biliary drainage for benign and malignant bile duct strictures.

Authors:  P Born; T Rösch; A Triptrap; E Frimberger; H D Allescher; R Ott; N Weigert; R Lorenz; M Classen
Journal:  Scand J Gastroenterol       Date:  1998-05       Impact factor: 2.423

5.  Role of self-expandable metal stents in the palliation of malignant duodenal obstruction.

Authors:  M Kaw; S Singh; H Gagneja; P Azad
Journal:  Surg Endosc       Date:  2002-10-31       Impact factor: 4.584

6.  The role of percutaneous nephrostomy in malignant ureteric obstruction.

Authors:  J R Wilson; G H Urwin; M J Stower
Journal:  Ann R Coll Surg Engl       Date:  2005-01       Impact factor: 1.891

7.  Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI.

Authors:  D L Buckley; P J Drew; S Mussurakis; J R Monson; A Horsman
Journal:  J Magn Reson Imaging       Date:  1997 May-Jun       Impact factor: 4.813

8.  Metal stents for malignant colorectal obstruction.

Authors:  Alessandro Repici; Nico Pagano; Cristina Marfinati Hervoso; Silvio Danese; Rinaldo Nicita; Paoletta Preatoni; Alberto Malesci
Journal:  Minim Invasive Ther Allied Technol       Date:  2006       Impact factor: 2.442

9.  Metallic stents for malignant and benign ureteric obstruction.

Authors:  M Wakui; S Takeuchi; J Isioka; K Iwabuchi; S Morimoto
Journal:  BJU Int       Date:  2000-02       Impact factor: 5.588

10.  Self-expandable stent before elective surgery vs. emergency surgery for the treatment of malignant colorectal obstructions: comparison of primary anastomosis and morbidity rates.

Authors:  Cristina Martinez-Santos; Rosa F Lobato; José Manuel Fradejas; Isabel Pinto; Pablo Ortega-Deballón; Mariano Moreno-Azcoita
Journal:  Dis Colon Rectum       Date:  2002-03       Impact factor: 4.585

View more
  1 in total

1.  The challenge of sustainability in healthcare systems: frequency and cost of diagnostic procedures in end-of-life cancer patients.

Authors:  Ilaria Massa; William Balzi; Mattia Altini; Raffaella Bertè; Monica Bosco; Davide Cassinelli; Valentina Vignola; Luigi Cavanna; Flavia Foca; Monia Dall'Agata; Oriana Nanni; Romina Rossi; Marco Maltoni
Journal:  Support Care Cancer       Date:  2018-02-01       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.